Literature DB >> 22285962

Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy.

Monir Shababi1, Javad Habibi, Lixin Ma, Jacqueline J Glascock, James R Sowers, Christian L Lorson.   

Abstract

Spinal muscular atrophy (SMA) is a leading genetic cause of infantile death. Loss of a gene called Survival Motor Neuron 1 (SMN1) and, as a result, reduced levels of the Survival Motor Neuron (SMN) protein leads to SMA development. SMA is characterized by the loss of functional motor neurons in the spinal cord. However, accumulating evidence suggests the contribution of other organs to the composite SMA phenotype and disease progression. A growing number of congenital heart defects have been identified in severe SMA patients. Consistent with the clinical cases, we have recently identified developmental and functional heart defects in two SMA mouse models, occurring at embryonic stage in a severe SMA model and shortly after birth in a less severe model (SMN∆7). Our goal was to examine the late stage cardiac abnormalities in untreated SMN∆7 mice and to determine whether gene replacement therapy restores cardiac structure/function in rescued SMN∆7 model. To reveal the extent of the cardiac structural/functional repair in the rescued mice, we analyzed the heart of untreated and treated SMN∆7 model using self-complementary Adeno-associated virus (serotype 9) expressing the full-length SMN cDNA. We examined the characteristics of the heart failure such as remodeling, fibrosis, oxidative stress, and vascular integrity in both groups. Our results clearly indicate that fibrosis, oxidative stress activation, vascular remodeling, and a significant decrease in the number of capillaries exist in the SMA heart. The cardiac structural defects were improved drastically in the rescued animals, however, the level of impairment was still significant compared to the age-matched wildtype littermates. Furthermore, functional analysis by in vivo cardiac magnetic resonance imaging (MRI) revealed that the heart of the treated SMA mice still exhibits functional defects. In conclusion, cardiac abnormalities are only partially rescued in post-birth treated SMA animals and these abnormalities may contribute to the premature death of vector-treated SMA animals with seemingly rescued motor function but an average life span of less than 70 days as reported in several studies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285962      PMCID: PMC3327806          DOI: 10.1016/j.yjmcc.2012.01.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  54 in total

Review 1.  Energy metabolism in heart failure and remodelling.

Authors:  Joanne S Ingwall
Journal:  Cardiovasc Res       Date:  2008-11-05       Impact factor: 10.787

2.  Congenital heart disease is a feature of severe infantile spinal muscular atrophy.

Authors:  S Rudnik-Schöneborn; R Heller; C Berg; C Betzler; T Grimm; T Eggermann; K Eggermann; R Wirth; B Wirth; K Zerres
Journal:  J Med Genet       Date:  2008-07-28       Impact factor: 6.318

3.  Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy.

Authors:  Matthew E R Butchbach; Ferrill F Rose; Sarah Rhoades; John Marston; John T McCrone; Rachel Sinnott; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2009-11-27       Impact factor: 3.575

4.  Vascular perfusion abnormalities in infants with spinal muscular atrophy.

Authors:  Alexandra prufer de Queiroz Campos Araujo; Mario Araujo; Kathryn J Swoboda
Journal:  J Pediatr       Date:  2009-08       Impact factor: 4.406

5.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Authors:  Kevin D Foust; Emily Nurre; Chrystal L Montgomery; Anna Hernandez; Curtis M Chan; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

6.  Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.

Authors:  Vincent G DeMarco; Javad Habibi; Adam T Whaley-Connell; Rebecca I Schneider; James R Sowers; Bradley T Andresen; Alex A Gutweiler; Lixin Ma; Megan S Johnson; Carlos M Ferrario; Kevin C Dellsperger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-24       Impact factor: 4.733

7.  Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat.

Authors:  Lawrence T Bish; Kevin Morine; Meg M Sleeper; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H Lee Sweeney
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

8.  Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats.

Authors:  Manuela Aragno; Raffaella Mastrocola; Giuseppe Alloatti; Ilenia Vercellinatto; Paola Bardini; Stefano Geuna; Maria Graziella Catalano; Oliviero Danni; Giuseppe Boccuzzi
Journal:  Endocrinology       Date:  2007-09-27       Impact factor: 4.736

9.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN.

Authors:  Kevin D Foust; Xueyong Wang; Vicki L McGovern; Lyndsey Braun; Adam K Bevan; Amanda M Haidet; Thanh T Le; Pablo R Morales; Mark M Rich; Arthur H M Burghes; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2010-02-28       Impact factor: 68.164

10.  Development of a single vector system that enhances trans-splicing of SMN2 transcripts.

Authors:  Tristan H Coady; Travis D Baughan; Monir Shababi; Marco A Passini; Christian L Lorson
Journal:  PLoS One       Date:  2008-10-22       Impact factor: 3.240

View more
  34 in total

1.  The effect of diet on the protective action of D156844 observed in spinal muscular atrophy mice.

Authors:  Matthew E R Butchbach; Jasbir Singh; Mark E Gurney; Arthur H M Burghes
Journal:  Exp Neurol       Date:  2014-03-25       Impact factor: 5.330

Review 2.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

3.  Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy.

Authors:  Laurent P Bogdanik; Melissa A Osborne; Crystal Davis; Whitney P Martin; Andrew Austin; Frank Rigo; C Frank Bennett; Cathleen M Lutz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

4.  AAV9-DOK7 gene therapy reduces disease severity in Smn2B/- SMA model mice.

Authors:  Kevin A Kaifer; Eric Villalón; Caley E Smith; Madeline E Simon; Jose Marquez; Abigail E Hopkins; Toni I Morcos; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2020-07-30       Impact factor: 3.575

5.  Development of a novel severe mouse model of spinal muscular atrophy with respiratory distress type 1: FVB-nmd.

Authors:  Monir Shababi; Caley E Smith; Mona Kacher; Zayd Alrawi; Eric Villalón; Daniel Davis; Elizabeth C Bryda; Christian L Lorson
Journal:  Biochem Biophys Res Commun       Date:  2019-10-08       Impact factor: 3.575

Review 6.  Antisense oligonucleotides for the treatment of spinal muscular atrophy.

Authors:  Paul N Porensky; Arthur H M Burghes
Journal:  Hum Gene Ther       Date:  2013-05       Impact factor: 5.695

7.  Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy.

Authors:  Matthew E R Butchbach; Casey J Lumpkin; Ashlee W Harris; Luciano Saieva; Jonathan D Edwards; Eileen Workman; Louise R Simard; Livio Pellizzoni; Arthur H M Burghes
Journal:  Exp Neurol       Date:  2016-02-15       Impact factor: 5.330

Review 8.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

9.  The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy.

Authors:  W Arnold; Vicki L McGovern; Benjamin Sanchez; Jia Li; Kaitlyn M Corlett; Stephen J Kolb; Seward B Rutkove; Arthur H Burghes
Journal:  Neurobiol Dis       Date:  2015-12-28       Impact factor: 5.996

Review 10.  Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?

Authors:  Monir Shababi; Christian L Lorson; Sabine S Rudnik-Schöneborn
Journal:  J Anat       Date:  2013-07-22       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.